Does Aetna Cover Lantus?

How Aetna Classifies Lantus on Its Formulary

Aetna organizes covered medications into tiers that determine how much you pay at the pharmacy. Lantus (insulin glargine U-100), manufactured by Sanofi, appears on most Aetna commercial formularies as a non-preferred brand product. This means the drug is covered but carries higher out-of-pocket costs than preferred-tier insulins.

Understanding Aetna's Tier Structure

Most Aetna plans use a four- or five-tier formulary. Tier 1 includes generics, Tier 2 holds preferred brands, Tier 3 contains non-preferred brands, and Tier 4 (or a specialty tier) covers high-cost medications. Lantus commonly falls on Tier 3. A 2023 analysis of commercial insurance formularies found that 68% of large insurers placed at least one insulin glargine biosimilar on a preferred tier while moving the originator product to a higher cost-sharing level [1].

What Non-Preferred Status Means for Your Wallet

Non-preferred brand placement translates to a copay typically ranging from $50 to $150 per 30-day supply, or coinsurance of 30% to 50% of the drug's list price after any negotiated discounts. By contrast, a preferred-tier biosimilar may carry a $25 to $50 copay. The difference adds up fast. Over 12 months, choosing a non-preferred brand over a preferred biosimilar could cost an extra $600 to $1,200 out of pocket.

Checking Your Specific Plan

Aetna administers hundreds of distinct plan designs for employers, exchanges, and government programs. Your plan's Summary of Benefits and Coverage (SBC) and the pharmacy formulary search tool on Aetna's member portal are the definitive sources for your tier placement. Formulary status can change at plan renewal, so verify coverage annually or whenever your employer switches plan options.

Lantus Coverage Under Aetna Medicare Advantage and Part D

For Medicare beneficiaries enrolled in Aetna Medicare Advantage plans, Lantus coverage follows Part D prescription drug benefit rules. The Inflation Reduction Act's $35 monthly insulin cost-sharing cap, which took full effect in January 2025, applies to all covered insulin products under Part D, including Lantus [2].

The $35 Insulin Cap

This cap means that regardless of whether Lantus sits on a preferred or non-preferred tier, your monthly copay will not exceed $35 during the initial coverage phase, the coverage gap, and the catastrophic phase. Before this federal provision, some Medicare enrollees paid over $100 per month for Lantus during the coverage gap. The cap does not reduce your plan's negotiated price or affect how the cost counts toward your deductible and true out-of-pocket (TrOOP) threshold.

Formulary Variations Across Aetna Medicare Plans

Aetna offers different Medicare Part D and Medicare Advantage Prescription Drug (MAPD) plans in different regions. Some Aetna Medicare plans list Semglee (insulin glargine-yfgn) as the preferred basal insulin and apply step therapy requiring a trial of the biosimilar before covering Lantus. If your physician determines that brand Lantus is medically necessary due to documented clinical reasons (device familiarity, prior adverse reaction to a biosimilar, or glycemic instability on switching), a coverage determination request can override step therapy.

A retrospective cohort study of 1,465 patients switching from originator insulin glargine to biosimilar insulin glargine found no statistically significant difference in HbA1c change (-0.02%, 95% CI: -0.09 to 0.05) over 6 months, supporting formulary-driven substitution [3].

Biosimilar Alternatives Preferred by Aetna

Aetna, like most large payers, has increasingly favored biosimilar insulin glargine products over the originator Lantus. This shift accelerated after the FDA approved multiple interchangeable biosimilars and the Centers for Medicare & Medicaid Services (CMS) encouraged their adoption to lower insulin spending [4].

Semglee (Insulin Glargine-yfgn)

Semglee, manufactured by Biocon/Viatris, was the first interchangeable biosimilar insulin product designated by the FDA in July 2021. "Interchangeable" status means a pharmacist can substitute Semglee for Lantus at the pharmacy counter without contacting the prescriber, depending on state law. Semglee is available in both vial and prefilled pen presentations. On many Aetna plans, Semglee sits on Tier 2 with a copay roughly half that of brand Lantus.

Rezvoglar (Insulin Glargine-aglr)

Rezvoglar, from Eli Lilly, received FDA approval as a biosimilar to Lantus in December 2021. It is available as a KwikPen prefilled device delivering 300 units per pen. Some Aetna formularies list Rezvoglar as an additional preferred option, particularly on plans with Lilly rebate agreements.

Clinical Equivalence Data

The INSTRIDE trials compared biosimilar insulin glargine to Lantus in patients with type 1 and type 2 diabetes. INSTRIDE 1 (N=558) demonstrated equivalent HbA1c reduction at 24 weeks, with a treatment difference of 0.05% (95% CI: -0.12 to 0.22), falling within the predefined equivalence margin [5]. Switching between products mid-treatment did not increase hypoglycemia rates or require dose adjustments in 89% of patients.

Prior Authorization and Step Therapy Requirements

Not every Aetna plan requires prior authorization for Lantus, but step therapy protocols are common. Step therapy means your plan expects you to try a preferred insulin glargine product before it will cover the non-preferred brand at the lower cost-share.

How Step Therapy Works in Practice

Your prescriber writes for Lantus. The pharmacy submits the claim. If your plan has step therapy, the claim rejects with a message indicating that a preferred alternative should be tried first. Your prescriber can either switch the prescription to the preferred biosimilar or submit a step therapy exception request explaining why you need brand Lantus specifically.

Grounds for a Formulary Exception

The American Diabetes Association (ADA) Standards of Care emphasize that insulin therapy should be individualized and that switching insulin products should involve shared decision-making between patient and provider [6]. Valid reasons for an exception request include:

• Documented hypoglycemic events or glycemic instability after biosimilar trial
• Patient inability to use the biosimilar delivery device due to dexterity or visual limitations
• Prior adverse reaction to an inactive ingredient in the biosimilar formulation
• Prescriber clinical judgment that the risk of switching outweighs cost savings

Aetna must respond to a standard exception request within 72 hours for non-urgent cases or 24 hours for expedited requests under Medicare Part D regulations.

Quantity Limits and Supply Restrictions

Aetna may impose quantity limits based on labeled dosing. For Lantus SoloStar pens (3 mL, 300 units per pen), a typical limit is 5 pens per 30 days, corresponding to approximately 50 units per day. Patients on higher doses may need their prescriber to submit clinical documentation supporting the higher quantity. Mail-order pharmacy through Aetna's preferred mail service (often CVS Caremark) can provide 90-day supplies, sometimes at a lower per-unit cost.

Out-of-Pocket Cost Strategies for Aetna Members

Even with insurance coverage, insulin costs remain a financial burden for many Americans. A 2024 survey by the ADA found that 1 in 4 people with diabetes reported rationing insulin due to cost at least once in the prior year [7]. Several strategies can reduce what you pay for Lantus or its alternatives through Aetna.

Sanofi's Insulins ValYou Savings Program

Sanofi offers the Insulins ValYou Savings Program for patients without insurance or those whose insurance does not cover Lantus. Eligible patients pay $35 per 30-day vial supply or $55 per 30-day pen supply. This program is not valid with Medicare, Medicaid, or other federal programs.

Aetna's Insulin Cost-Sharing Initiatives

Some Aetna employer-sponsored plans have adopted flat copay insulin programs that cap insulin cost-sharing at $25 to $50 per month regardless of tier placement. These programs vary by employer. Check with your benefits administrator to see if your specific plan participates.

Patient Assistance From Sanofi

For uninsured or underinsured patients, Sanofi Patient Connection provides free Lantus to individuals meeting income criteria (generally below 400% of the federal poverty level). The application requires prescriber involvement and income verification. Processing takes 4 to 6 weeks.

340B Program Access

Patients receiving care at 340B-covered entities (federally qualified health centers, certain hospitals, and Ryan White HIV/AIDS clinics) may access Lantus at significantly reduced acquisition cost. The savings may or may not be passed directly to the patient depending on the entity's policy.

How Lantus Compares to Other Basal Insulins on Aetna

Aetna covers several basal insulin options beyond Lantus and its biosimilars. The choice between them depends on clinical factors, device preference, and formulary tier.

Levemir (Insulin Detemir)

Levemir is a long-acting insulin analog with a duration of action up to 24 hours but often dosed twice daily. It is being phased out of many formularies as Novo Nordisk shifts focus to Tresiba. The SWITCH 2 trial (N=721) comparing insulin degludec to insulin glargine U-100 in type 2 diabetes showed a 30% lower rate of overall symptomatic hypoglycemia with degludec (rate ratio 0.70, 95% CI: 0.61-0.80, P<0.001) [8].

Tresiba (Insulin Degludec)

Tresiba provides an ultra-long duration of action exceeding 42 hours, allowing flexible dosing timing. It often sits on Tier 3 or specialty tier on Aetna plans. Tresiba may be preferred for patients with recurrent nocturnal hypoglycemia or highly variable schedules.

Toujeo (Insulin Glargine U-300)

Toujeo delivers the same insulin glargine molecule as Lantus but at three times the concentration (300 units/mL vs. 100 units/mL). The EDITION trial program showed Toujeo produced comparable HbA1c reduction to Lantus with fewer confirmed nocturnal hypoglycemic events (relative risk 0.75, P=0.004) in type 2 diabetes [9]. Toujeo's formulary placement on Aetna varies but is typically Tier 3.

Basaglar (Insulin Glargine, Lilly)

Basaglar was the first follow-on insulin glargine product in the U.S. It preceded the interchangeable biosimilar designation pathway and is classified as a biosimilar but not interchangeable. Some Aetna plans still list Basaglar alongside or instead of Semglee as a preferred option.

What to Do If Aetna Denies Lantus Coverage

A coverage denial does not have to be the final answer. Federal and state regulations give you the right to appeal, and the process is straightforward.

Internal Appeal

File a written appeal within 180 days of the denial notice (60 days for Medicare Part D plans). Include a letter from your prescriber explaining why Lantus is medically necessary, relevant clinical documentation (lab results, glucose logs, prior medication trials), and any supporting literature. Aetna must respond within 30 days for pre-service appeals or 60 days for post-service appeals on commercial plans.

External Review

If the internal appeal is denied, you can request an independent external review. An external review organization (ERO) not affiliated with Aetna will evaluate the case. For commercial plans governed by the ACA, external review is available in all 50 states. For Medicare plans, the appeal escalates through the Part D appeals process to an independent review entity (IRE) and, if needed, to an administrative law judge.

State Insurance Department Complaints

If you believe Aetna is not following its own formulary rules or applicable state insulin access laws, you can file a complaint with your state's department of insurance. As of 2025, 25 states have enacted insulin copay cap laws for state-regulated commercial plans, with caps ranging from $25 to $100 per 30-day supply [10].

Practical Steps to Get Lantus Covered by Aetna

The fastest path to filling your Lantus prescription with Aetna coverage involves a specific sequence of actions your care team can take.

Step 1: Verify Formulary Status

Log in to the Aetna member portal or call the number on the back of your card. Ask specifically: Is Lantus on my formulary, what tier, and are there step therapy or prior authorization requirements?

Step 2: Discuss Biosimilar Options With Your Prescriber

If a biosimilar is preferred and you have no clinical contraindication, switching to Semglee or Rezvoglar will lower your copay without changing your glycemic control. The FDA's interchangeability designation means the biosimilar meets the same safety, purity, and potency standards as the originator [11].

Step 3: Apply for Copay Assistance if Needed

If your copay exceeds your budget, ask your prescriber's office to help you apply for the Sanofi savings program or a patient assistance foundation. The nonprofit organizations such as the HealthWell Foundation and the Patient Access Network (PAN) Foundation offer copay assistance grants specifically for insulin.

Step 4: Appeal if Denied

Do not abandon the appeal process after a first denial. Data from CMS show that roughly 50% of Part D coverage determination appeals result in a favorable outcome for the beneficiary when clinical documentation is included [12].

Aetna covers Lantus on most plans, and the $35 Medicare insulin cap makes it more affordable than ever for Part D enrollees. For commercial plan members paying a high non-preferred copay, switching to a preferred biosimilar insulin glargine saves $600 or more annually with equivalent glycemic outcomes.